Literature DB >> 19653289

World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010.

Charles N Bernstein, Michael Fried, J H Krabshuis, Henry Cohen, R Eliakim, Suleiman Fedail, Richard Gearry, K L Goh, Saheed Hamid, Aamir Ghafor Khan, A W LeMair, Qin Ouyang, J F Rey, Ajit Sood, Flavio Steinwurz, Ole O Thomsen, Alan Thomson, Gillian Watermeyer.   

Abstract

Inflammatory bowel disease (IBD) represents a group of idiopathic, chronic, inflammatory intestinal conditions. Its two main disease categories are: Crohn's disease (CD) and ulcerative colitis (UC), which feature both overlapping and distinct clinical and pathological features. While these diseases have, in the past, been most evident in the developed world, their prevalence in the developing world has been gradually increasing in recent decades. This poses unique issues in diagnosis and management which have been scarcely addressed in the literature or in extant guidelines. Depending on the nature of the complaints, investigations to diagnose either form of IBD or to assess disease activity will vary and will also be influenced by geographic variations in other conditions that might mimic IBD. Similarly, therapy varies depending on the phenotype of the disease being treated and available resources. The World Gastroenterology Organization has, accordingly, developed guidelines for diagnosing and treating IBD using a cascade approach to account for variability in resources in countries around the world.

Entities:  

Mesh:

Year:  2010        PMID: 19653289     DOI: 10.1002/ibd.21048

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  131 in total

Review 1.  Epidemiologic clues to inflammatory bowel disease.

Authors:  Charles N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2010-12

2.  Differences in clinical features of Crohn's disease and intestinal tuberculosis.

Authors:  Xin Huang; Wang-Di Liao; Chen Yu; Yi Tu; Xiao-Lin Pan; You-Xiang Chen; Nong-Hua Lv; Xuan Zhu
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 3.  Effectiveness of interferon-gamma release assays for differentiating intestinal tuberculosis from Crohn's disease: a meta-analysis.

Authors:  Wen Chen; Jun-Hua Fan; Wei Luo; Peng Peng; Si-Biao Su
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

4.  Fecal Microbiota Transplant via Endoscopic Delivering Through Small Intestine and Colon: No Difference for Crohn's Disease.

Authors:  Zhenyu Yang; Chibin Bu; Wei Yuan; Zhaohua Shen; Yongsheng Quan; Shuai Wu; Changxin Zhu; Xiaoyan Wang
Journal:  Dig Dis Sci       Date:  2019-07-31       Impact factor: 3.199

Review 5.  Current application of proteomics in biomarker discovery for inflammatory bowel disease.

Authors:  Patrick Py Chan; Valerie C Wasinger; Rupert W Leong
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

6.  CD4+CD29+T cells are blamed for the persistent inflammatory response in ulcerative colitis.

Authors:  Yuzhen Zhu; Yanling Feng; Hongbo Liu; Hua Ye; Cancan Guo; Jinshan Feng; Shixue Dai; Xuebao Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

7.  Paneth cell defects in Crohn's disease patients promote dysbiosis.

Authors:  Ta-Chiang Liu; Bhaskar Gurram; Megan T Baldridge; Richard Head; Vy Lam; Chengwei Luo; Yumei Cao; Pippa Simpson; Michael Hayward; Mary L Holtz; Pavlos Bousounis; Joshua Noe; Diana Lerner; Jose Cabrera; Vincent Biank; Michael Stephens; Curtis Huttenhower; Dermot Pb McGovern; Ramnik J Xavier; Thaddeus S Stappenbeck; Nita H Salzman
Journal:  JCI Insight       Date:  2016-06-02

Review 8.  Tools for primary care management of inflammatory bowel disease: do they exist?

Authors:  Alice L Bennett; Pia Munkholm; Jane M Andrews
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  Preoperative exercise capacity in adult inflammatory bowel disease sufferers, determined by cardiopulmonary exercise testing.

Authors:  J M Otto; A F O'Doherty; P J Hennis; K Mitchell; J S Pate; J A Cooper; M P W Grocott; H E Montgomery
Journal:  Int J Colorectal Dis       Date:  2012-07-29       Impact factor: 2.571

10.  Myelosuppression monitoring after immunomodulator initiation in veterans with inflammatory bowel disease: a national practice audit.

Authors:  J K Hou; J R Kramer; P Richardson; S Sansgiry; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2012-10-14       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.